Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study

A Sherbini, Ahmad; M. Gwinnutt, James; L Hyrich, Kimme; Co-Investigators, RAMS; Adebajo, Ade; Ahmed, Khalid; Al-Ansari, Atheer; Amarasena, Roshan; Bukhari, Marwan; Callan, Margaret; G Chelliah, E; Chinoy, Hector; Cooper, Annie; DasGupta, Bhaskar; J. Davis, Martin; Galloway, James; Gough, Andrew; Green, Michael; Gullick, Nicola; Hamilton, Jennifer; Hassan, Waji; Hider, Samantha; L Hyrich, Kimme; Kamath, Sanjeet; Knight, Susan; Lane, Suzanne; Lee, Martin; Levy, Sarah; Macphie, Lizzy; Marguerie, Christopher; Marshall, Tarnya; Mathews, Catherine; McKenna, Frank; Naz, Sophia; Perry, Mark; Pollard, Louise; Quilty, Brian; Robertson, Lindsay; Roy, Dipak; W. Sanders, Paul; Saravanan, V.; L. Scott, David; Smith, Gillian; Smith, Richard; Symmons, Deborah; Teh, Lee‐Suan; Viner, Nick; Verstappen, Suzanne

doi:10.1093/rheumatology/keab917

Public

Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study

Published in Lara D. Veeken • Jan 24, 2022

Authors:

Ahmad A Sherbini

James M. Gwinnutt

Kimme L Hyrich

Abstract

OBJECTIVES: To estimate prevalence rates and identify baseline predictors of adverse events (AEs) over the first year of treatment in patients with RA starting MTX. METHODS: Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of patients with RA starting MTX. Thi...

Subject

Medicine

Internal medicine

Mucocutaneous zone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!